BiondVax Pharmaceuticals (NASDAQ:BVXV) Downgraded by BidaskClub

BidaskClub downgraded shares of BiondVax Pharmaceuticals (NASDAQ:BVXV) from a hold rating to a sell rating in a research note published on Saturday, BidAskClub reports.

Separately, ValuEngine raised shares of BiondVax Pharmaceuticals from a hold rating to a buy rating in a report on Monday, August 3rd.

BiondVax Pharmaceuticals stock opened at $38.68 on Friday. BiondVax Pharmaceuticals has a 1-year low of $5.20 and a 1-year high of $62.00. The firm has a market capitalization of $445.63 million, a price-to-earnings ratio of -12.81 and a beta of 2.21. The firm has a 50 day simple moving average of $39.44 and a 200 day simple moving average of $28.30.

BiondVax Pharmaceuticals (NASDAQ:BVXV) last released its quarterly earnings data on Thursday, August 20th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($1.11). Equities research analysts anticipate that BiondVax Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in BVXV. HighTower Advisors LLC boosted its holdings in BiondVax Pharmaceuticals by 12.7% in the 1st quarter. HighTower Advisors LLC now owns 18,935 shares of the company’s stock valued at $146,000 after purchasing an additional 2,135 shares during the period. Royal Bank of Canada lifted its holdings in shares of BiondVax Pharmaceuticals by 286.1% during the 1st quarter. Royal Bank of Canada now owns 3,475 shares of the company’s stock worth $27,000 after acquiring an additional 2,575 shares during the last quarter. UBS Group AG bought a new stake in shares of BiondVax Pharmaceuticals during the 2nd quarter worth $43,000. Finally, Virtu Financial LLC bought a new stake in shares of BiondVax Pharmaceuticals during the 2nd quarter worth $260,000. 3.84% of the stock is owned by hedge funds and other institutional investors.

About BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus.

Further Reading: Stochastic Momentum Index (SMI)

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.